中华内科杂志
中華內科雜誌
중화내과잡지
CHINESE JOURNAL OF INTERNAL MEDICINE
2015年
9期
768-772
,共5页
夏昆%丁荣晶%杨渊%吴宝恒%张旗%胡大一
夏昆%丁榮晶%楊淵%吳寶恆%張旂%鬍大一
하곤%정영정%양연%오보항%장기%호대일
瘦素%脂联素%内脂素%高血压%肥胖症%女性
瘦素%脂聯素%內脂素%高血壓%肥胖癥%女性
수소%지련소%내지소%고혈압%비반증%녀성
Leptin%Adiponectin%Visfatin%Hypertension%Obesity%Female
目的 探讨血脂肪细胞因子瘦素、脂联素、内脂素水平与女性肥胖高血压的关系.方法 206例女性参与者,根据血压和BMI,分成4组:高血压肥胖组(48例);单纯高血压组(48例);单纯肥胖组(56例);正常对照组(54例).测定各组血清瘦素、脂联素和内脂素水平,分析其与血压、BMI和腰围的相关性.结果 瘦素水平在非肥胖组[单纯高血压组(4.47 ±1.26) ng/L;正常对照组(3.73 ±1.18)ng/L]显著高于肥胖组[高血压肥胖组(2.97 ±1.46) ng/L;单纯肥胖组(3.02±1.18) ng/L],在血压≥140/90 mmHg(1mmHg =0.133 kPa)组显著高于血压<140/90 mmHg组;脂联素水平在正常对照组[38.99 (19.75,103.71) μg/L]显著高于肥胖高血压组、单纯高血压组和单纯肥胖组,后3组间差异无统计学意义;无论有无肥胖,内脂素水平在高血压组[高血压肥胖组:3.84(3.40,5.35) ng/L;单纯高血压组:3.75 (1.63,6.67) ng/L]明显高于非高血压组[单纯肥胖组:3.19 (0.96,9.45) ng/L;正常对照组:3.23(1.92,4.64) ng/L].Logistics回归分析显示,肥胖者脂联素每降低1μg/L,高血压患病风险增加1.6%,腰围每增加1 cm,高血压患病风险增加8.3%;内脂素每增加1 ng/L,高血压患病风险增加5.45% (P< 0.05),与瘦素无相关.结论 脂联素、内脂素与女性血压和肥胖均相关,可能参与女性肥胖高血压的发生.
目的 探討血脂肪細胞因子瘦素、脂聯素、內脂素水平與女性肥胖高血壓的關繫.方法 206例女性參與者,根據血壓和BMI,分成4組:高血壓肥胖組(48例);單純高血壓組(48例);單純肥胖組(56例);正常對照組(54例).測定各組血清瘦素、脂聯素和內脂素水平,分析其與血壓、BMI和腰圍的相關性.結果 瘦素水平在非肥胖組[單純高血壓組(4.47 ±1.26) ng/L;正常對照組(3.73 ±1.18)ng/L]顯著高于肥胖組[高血壓肥胖組(2.97 ±1.46) ng/L;單純肥胖組(3.02±1.18) ng/L],在血壓≥140/90 mmHg(1mmHg =0.133 kPa)組顯著高于血壓<140/90 mmHg組;脂聯素水平在正常對照組[38.99 (19.75,103.71) μg/L]顯著高于肥胖高血壓組、單純高血壓組和單純肥胖組,後3組間差異無統計學意義;無論有無肥胖,內脂素水平在高血壓組[高血壓肥胖組:3.84(3.40,5.35) ng/L;單純高血壓組:3.75 (1.63,6.67) ng/L]明顯高于非高血壓組[單純肥胖組:3.19 (0.96,9.45) ng/L;正常對照組:3.23(1.92,4.64) ng/L].Logistics迴歸分析顯示,肥胖者脂聯素每降低1μg/L,高血壓患病風險增加1.6%,腰圍每增加1 cm,高血壓患病風險增加8.3%;內脂素每增加1 ng/L,高血壓患病風險增加5.45% (P< 0.05),與瘦素無相關.結論 脂聯素、內脂素與女性血壓和肥胖均相關,可能參與女性肥胖高血壓的髮生.
목적 탐토혈지방세포인자수소、지련소、내지소수평여녀성비반고혈압적관계.방법 206례녀성삼여자,근거혈압화BMI,분성4조:고혈압비반조(48례);단순고혈압조(48례);단순비반조(56례);정상대조조(54례).측정각조혈청수소、지련소화내지소수평,분석기여혈압、BMI화요위적상관성.결과 수소수평재비비반조[단순고혈압조(4.47 ±1.26) ng/L;정상대조조(3.73 ±1.18)ng/L]현저고우비반조[고혈압비반조(2.97 ±1.46) ng/L;단순비반조(3.02±1.18) ng/L],재혈압≥140/90 mmHg(1mmHg =0.133 kPa)조현저고우혈압<140/90 mmHg조;지련소수평재정상대조조[38.99 (19.75,103.71) μg/L]현저고우비반고혈압조、단순고혈압조화단순비반조,후3조간차이무통계학의의;무론유무비반,내지소수평재고혈압조[고혈압비반조:3.84(3.40,5.35) ng/L;단순고혈압조:3.75 (1.63,6.67) ng/L]명현고우비고혈압조[단순비반조:3.19 (0.96,9.45) ng/L;정상대조조:3.23(1.92,4.64) ng/L].Logistics회귀분석현시,비반자지련소매강저1μg/L,고혈압환병풍험증가1.6%,요위매증가1 cm,고혈압환병풍험증가8.3%;내지소매증가1 ng/L,고혈압환병풍험증가5.45% (P< 0.05),여수소무상관.결론 지련소、내지소여녀성혈압화비반균상관,가능삼여녀성비반고혈압적발생.
Objective This study was aimed to investigate the relationship between serum leptin,adiponectin,visfatin levels and obesity and essential hypertension in female subjects.Methods According to BMI and blood pressure,206 female participants enrolled were divided into four groups:group 1:obesity and hypertension (48 cases);group 2:non-obesity but hypertension (48 cases);group 3:obesity and normotension (56 cases) and group 4:normal BMI and blood pressure (54 cases).Serum leptin,adiponectin and visfatin levels were detected and their relationships to BMI,blood pressure and waist circumference were analysed.Results Serum leptin levels were significantly higher in non-obese groups [group 2:(4.47 ±1.26) ng/L,group 4:(3.73-±1.18)ng/L] than in obese groups [group 1:(2.97 ± 1.46) ng/L,group 3:(3.02 ± 1.18) ng/L],and higher in hypertension groups than in normotension groups.Serum adiponectin levels were obviously higher in group 4 [38.99 (19.75,103.71) μg/L] than in the other three groups.There were no significant differences in adiponectin levels among group 1,2 and 3.Serum levels of visfatin were lower in normotension groups [group 3:3.19 (0.96,9.45) ng/L;group 4:3.23 (1.92,4.64) ng/L] than in hypertension groups [group 1:3.84 (3.40,5.35) ng/L;group 2:3.75 (1.63,6.67) ng/L] irrespective of obesity.Logistics regression analysis showed that there was 1.6%,8.3%,or 5.45% increased risk for hypertension for each 1 μg/L decrease in adiponectin,1 cm increase in waist circumference,or 1 μg/L increase in visfatin level in obesity,respectively.No relationship could be viewed between leptin and hypertension.Conclusions Adiponectin and visfatin levels were correlated with obesity and blood pressure in females.Both adipokines may play a crucial role in the development of hypertension in female obesity.